A Mutation in the KCNE3 Potassium Channel Gene Is Associated with Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis

Hypokalemic Periodic Paralyses comprise diverse diseases characterized by acute and reversible attacks of severe muscle weakness, associated with low serum potassium. The most common causes are Familial Hypokalemic Periodic Paralysis (FHypoKPP), an autosomal dominant disease, and Thyrotoxic Hypokale...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical endocrinology and metabolism 2002-11, Vol.87 (11), p.4881-4884
Hauptverfasser: Dias Da Silva, Magnus R., Cerutti, Janete M., Arnaldi, Liliane A. T., Maciel, Rui M. B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4884
container_issue 11
container_start_page 4881
container_title The journal of clinical endocrinology and metabolism
container_volume 87
creator Dias Da Silva, Magnus R.
Cerutti, Janete M.
Arnaldi, Liliane A. T.
Maciel, Rui M. B.
description Hypokalemic Periodic Paralyses comprise diverse diseases characterized by acute and reversible attacks of severe muscle weakness, associated with low serum potassium. The most common causes are Familial Hypokalemic Periodic Paralysis (FHypoKPP), an autosomal dominant disease, and Thyrotoxic Hypokalemic Periodic Paralysis (THypoKPP), secondary to thyrotoxicosis. Symptoms of paralysis are similar in both diseases, distinguished by thyrotoxicosis present in THypoKPP. FHypoKPP is caused by mutations in ionic channel genes calcium (CACN1AS), sodium (SCN4A) and potassium (KCNE3). Since both diseases are similar, we tested the hypothesis that THypoKPP could carry the same mutations described in FHypoKPP, being the paralysis a genetically conditioned complication of thyrotoxicosis. In 15 patients with THypoKPP, using target-exon PCR, CSGE screening, and direct sequencing, we excluded known mutations in CACN1AS and SCN4A genes. On the other hand, we were able to identify the R83H mutation in the KCNE3 gene in one sporadic case of THypoKPP, a man who had been asymptomatic until developing thyrotoxicosis caused by Graves’ disease; we confirmed the disease-causing mutation in 2 of 3 descendants. R83H was recently found in two FHypoKPP unrelated families, in which the mutant decreased outward potassium flux, resulting in a more positive resting membrane potential. We, therefore, identified the first genetic defect in THypoKPP, a mutation in the KCNE3 gene.
doi_str_mv 10.1210/jc.2002-020698
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72649064</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/jc.2002-020698</oup_id><sourcerecordid>72649064</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-db0a03409efe1f8b287110328c9a3a01481386bb51c4330c4618a3d0fad317943</originalsourceid><addsrcrecordid>eNp1kd2L1DAUxYMo7rj66qMEBMGHjvmatnkchnV3cdUFV_AtpOktk7FNukmK9sH_3QwdXBD26R64v3s4l4PQa0rWlFHy4WDWjBBWEEZKWT9BKyrFpqiorJ6iVV7QQlbsxxl6EeOBECrEhj9HZ5QJKmrBV-jPFn-ekk7WO2wdTnvAn3ZfLji-9UnHaKcB7_baOejxJTjA1xFvY_TG6gQt_mXTHn-booEx2cb2Ns04eXy3n4NP_rc1-Goe_U_dw5D1LQTr26PQQfdztPEletbpPsKr0zxH3z9e3O2uipuvl9e77U1hBJepaBuiCRdEQge0qxtWV5QSzmojNdf5q5ryumyaDc08J0aUtNa8JZ1uOa2k4Ofo3eI7Bn8_QUxqsDl032sHfoqqYqWQpDyCb_8DD34KLmdTnJY8E1VJMrVeKBN8jAE6NQY76DArStSxFnUw6liLWmrJB29OtlMzQPuAn3rIwPsF8NP4mFnxz2yzsOBab4J1MAaI8SHpIyH-AiOhpWE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3163643760</pqid></control><display><type>article</type><title>A Mutation in the KCNE3 Potassium Channel Gene Is Associated with Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Dias Da Silva, Magnus R. ; Cerutti, Janete M. ; Arnaldi, Liliane A. T. ; Maciel, Rui M. B.</creator><creatorcontrib>Dias Da Silva, Magnus R. ; Cerutti, Janete M. ; Arnaldi, Liliane A. T. ; Maciel, Rui M. B.</creatorcontrib><description>Hypokalemic Periodic Paralyses comprise diverse diseases characterized by acute and reversible attacks of severe muscle weakness, associated with low serum potassium. The most common causes are Familial Hypokalemic Periodic Paralysis (FHypoKPP), an autosomal dominant disease, and Thyrotoxic Hypokalemic Periodic Paralysis (THypoKPP), secondary to thyrotoxicosis. Symptoms of paralysis are similar in both diseases, distinguished by thyrotoxicosis present in THypoKPP. FHypoKPP is caused by mutations in ionic channel genes calcium (CACN1AS), sodium (SCN4A) and potassium (KCNE3). Since both diseases are similar, we tested the hypothesis that THypoKPP could carry the same mutations described in FHypoKPP, being the paralysis a genetically conditioned complication of thyrotoxicosis. In 15 patients with THypoKPP, using target-exon PCR, CSGE screening, and direct sequencing, we excluded known mutations in CACN1AS and SCN4A genes. On the other hand, we were able to identify the R83H mutation in the KCNE3 gene in one sporadic case of THypoKPP, a man who had been asymptomatic until developing thyrotoxicosis caused by Graves’ disease; we confirmed the disease-causing mutation in 2 of 3 descendants. R83H was recently found in two FHypoKPP unrelated families, in which the mutant decreased outward potassium flux, resulting in a more positive resting membrane potential. We, therefore, identified the first genetic defect in THypoKPP, a mutation in the KCNE3 gene.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2002-020698</identifier><identifier>PMID: 12414843</identifier><language>eng</language><publisher>United States: Endocrine Society</publisher><subject>Adult ; Antithyroid Agents - therapeutic use ; Calcium channels ; Disease ; Genes ; Genetic Predisposition to Disease ; Graves' disease ; Humans ; Hypokalemic Periodic Paralysis - drug therapy ; Hypokalemic Periodic Paralysis - genetics ; Iodine Radioisotopes - therapeutic use ; KCNE3 gene ; Male ; Membrane potential ; Membrane Potentials ; Methimazole - therapeutic use ; Mutation ; Paralysis ; Pedigree ; Polymerase Chain Reaction ; Potassium ; Potassium Channels - genetics ; Potassium Channels, Voltage-Gated ; Potassium Chloride - therapeutic use ; Sodium channels ; Thyrotoxicosis ; Thyrotoxicosis - complications ; Thyrotoxicosis - genetics ; Thyrotoxicosis - therapy</subject><ispartof>The journal of clinical endocrinology and metabolism, 2002-11, Vol.87 (11), p.4881-4884</ispartof><rights>Copyright © 2002 by The Endocrine Society 2002</rights><rights>Copyright © 2002 by The Endocrine Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-db0a03409efe1f8b287110328c9a3a01481386bb51c4330c4618a3d0fad317943</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12414843$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dias Da Silva, Magnus R.</creatorcontrib><creatorcontrib>Cerutti, Janete M.</creatorcontrib><creatorcontrib>Arnaldi, Liliane A. T.</creatorcontrib><creatorcontrib>Maciel, Rui M. B.</creatorcontrib><title>A Mutation in the KCNE3 Potassium Channel Gene Is Associated with Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Hypokalemic Periodic Paralyses comprise diverse diseases characterized by acute and reversible attacks of severe muscle weakness, associated with low serum potassium. The most common causes are Familial Hypokalemic Periodic Paralysis (FHypoKPP), an autosomal dominant disease, and Thyrotoxic Hypokalemic Periodic Paralysis (THypoKPP), secondary to thyrotoxicosis. Symptoms of paralysis are similar in both diseases, distinguished by thyrotoxicosis present in THypoKPP. FHypoKPP is caused by mutations in ionic channel genes calcium (CACN1AS), sodium (SCN4A) and potassium (KCNE3). Since both diseases are similar, we tested the hypothesis that THypoKPP could carry the same mutations described in FHypoKPP, being the paralysis a genetically conditioned complication of thyrotoxicosis. In 15 patients with THypoKPP, using target-exon PCR, CSGE screening, and direct sequencing, we excluded known mutations in CACN1AS and SCN4A genes. On the other hand, we were able to identify the R83H mutation in the KCNE3 gene in one sporadic case of THypoKPP, a man who had been asymptomatic until developing thyrotoxicosis caused by Graves’ disease; we confirmed the disease-causing mutation in 2 of 3 descendants. R83H was recently found in two FHypoKPP unrelated families, in which the mutant decreased outward potassium flux, resulting in a more positive resting membrane potential. We, therefore, identified the first genetic defect in THypoKPP, a mutation in the KCNE3 gene.</description><subject>Adult</subject><subject>Antithyroid Agents - therapeutic use</subject><subject>Calcium channels</subject><subject>Disease</subject><subject>Genes</subject><subject>Genetic Predisposition to Disease</subject><subject>Graves' disease</subject><subject>Humans</subject><subject>Hypokalemic Periodic Paralysis - drug therapy</subject><subject>Hypokalemic Periodic Paralysis - genetics</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>KCNE3 gene</subject><subject>Male</subject><subject>Membrane potential</subject><subject>Membrane Potentials</subject><subject>Methimazole - therapeutic use</subject><subject>Mutation</subject><subject>Paralysis</subject><subject>Pedigree</subject><subject>Polymerase Chain Reaction</subject><subject>Potassium</subject><subject>Potassium Channels - genetics</subject><subject>Potassium Channels, Voltage-Gated</subject><subject>Potassium Chloride - therapeutic use</subject><subject>Sodium channels</subject><subject>Thyrotoxicosis</subject><subject>Thyrotoxicosis - complications</subject><subject>Thyrotoxicosis - genetics</subject><subject>Thyrotoxicosis - therapy</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kd2L1DAUxYMo7rj66qMEBMGHjvmatnkchnV3cdUFV_AtpOktk7FNukmK9sH_3QwdXBD26R64v3s4l4PQa0rWlFHy4WDWjBBWEEZKWT9BKyrFpqiorJ6iVV7QQlbsxxl6EeOBECrEhj9HZ5QJKmrBV-jPFn-ekk7WO2wdTnvAn3ZfLji-9UnHaKcB7_baOejxJTjA1xFvY_TG6gQt_mXTHn-booEx2cb2Ns04eXy3n4NP_rc1-Goe_U_dw5D1LQTr26PQQfdztPEletbpPsKr0zxH3z9e3O2uipuvl9e77U1hBJepaBuiCRdEQge0qxtWV5QSzmojNdf5q5ryumyaDc08J0aUtNa8JZ1uOa2k4Ofo3eI7Bn8_QUxqsDl032sHfoqqYqWQpDyCb_8DD34KLmdTnJY8E1VJMrVeKBN8jAE6NQY76DArStSxFnUw6liLWmrJB29OtlMzQPuAn3rIwPsF8NP4mFnxz2yzsOBab4J1MAaI8SHpIyH-AiOhpWE</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>Dias Da Silva, Magnus R.</creator><creator>Cerutti, Janete M.</creator><creator>Arnaldi, Liliane A. T.</creator><creator>Maciel, Rui M. B.</creator><general>Endocrine Society</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>200211</creationdate><title>A Mutation in the KCNE3 Potassium Channel Gene Is Associated with Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis</title><author>Dias Da Silva, Magnus R. ; Cerutti, Janete M. ; Arnaldi, Liliane A. T. ; Maciel, Rui M. B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-db0a03409efe1f8b287110328c9a3a01481386bb51c4330c4618a3d0fad317943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Antithyroid Agents - therapeutic use</topic><topic>Calcium channels</topic><topic>Disease</topic><topic>Genes</topic><topic>Genetic Predisposition to Disease</topic><topic>Graves' disease</topic><topic>Humans</topic><topic>Hypokalemic Periodic Paralysis - drug therapy</topic><topic>Hypokalemic Periodic Paralysis - genetics</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>KCNE3 gene</topic><topic>Male</topic><topic>Membrane potential</topic><topic>Membrane Potentials</topic><topic>Methimazole - therapeutic use</topic><topic>Mutation</topic><topic>Paralysis</topic><topic>Pedigree</topic><topic>Polymerase Chain Reaction</topic><topic>Potassium</topic><topic>Potassium Channels - genetics</topic><topic>Potassium Channels, Voltage-Gated</topic><topic>Potassium Chloride - therapeutic use</topic><topic>Sodium channels</topic><topic>Thyrotoxicosis</topic><topic>Thyrotoxicosis - complications</topic><topic>Thyrotoxicosis - genetics</topic><topic>Thyrotoxicosis - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dias Da Silva, Magnus R.</creatorcontrib><creatorcontrib>Cerutti, Janete M.</creatorcontrib><creatorcontrib>Arnaldi, Liliane A. T.</creatorcontrib><creatorcontrib>Maciel, Rui M. B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dias Da Silva, Magnus R.</au><au>Cerutti, Janete M.</au><au>Arnaldi, Liliane A. T.</au><au>Maciel, Rui M. B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Mutation in the KCNE3 Potassium Channel Gene Is Associated with Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2002-11</date><risdate>2002</risdate><volume>87</volume><issue>11</issue><spage>4881</spage><epage>4884</epage><pages>4881-4884</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Hypokalemic Periodic Paralyses comprise diverse diseases characterized by acute and reversible attacks of severe muscle weakness, associated with low serum potassium. The most common causes are Familial Hypokalemic Periodic Paralysis (FHypoKPP), an autosomal dominant disease, and Thyrotoxic Hypokalemic Periodic Paralysis (THypoKPP), secondary to thyrotoxicosis. Symptoms of paralysis are similar in both diseases, distinguished by thyrotoxicosis present in THypoKPP. FHypoKPP is caused by mutations in ionic channel genes calcium (CACN1AS), sodium (SCN4A) and potassium (KCNE3). Since both diseases are similar, we tested the hypothesis that THypoKPP could carry the same mutations described in FHypoKPP, being the paralysis a genetically conditioned complication of thyrotoxicosis. In 15 patients with THypoKPP, using target-exon PCR, CSGE screening, and direct sequencing, we excluded known mutations in CACN1AS and SCN4A genes. On the other hand, we were able to identify the R83H mutation in the KCNE3 gene in one sporadic case of THypoKPP, a man who had been asymptomatic until developing thyrotoxicosis caused by Graves’ disease; we confirmed the disease-causing mutation in 2 of 3 descendants. R83H was recently found in two FHypoKPP unrelated families, in which the mutant decreased outward potassium flux, resulting in a more positive resting membrane potential. We, therefore, identified the first genetic defect in THypoKPP, a mutation in the KCNE3 gene.</abstract><cop>United States</cop><pub>Endocrine Society</pub><pmid>12414843</pmid><doi>10.1210/jc.2002-020698</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-972X
ispartof The journal of clinical endocrinology and metabolism, 2002-11, Vol.87 (11), p.4881-4884
issn 0021-972X
1945-7197
language eng
recordid cdi_proquest_miscellaneous_72649064
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Antithyroid Agents - therapeutic use
Calcium channels
Disease
Genes
Genetic Predisposition to Disease
Graves' disease
Humans
Hypokalemic Periodic Paralysis - drug therapy
Hypokalemic Periodic Paralysis - genetics
Iodine Radioisotopes - therapeutic use
KCNE3 gene
Male
Membrane potential
Membrane Potentials
Methimazole - therapeutic use
Mutation
Paralysis
Pedigree
Polymerase Chain Reaction
Potassium
Potassium Channels - genetics
Potassium Channels, Voltage-Gated
Potassium Chloride - therapeutic use
Sodium channels
Thyrotoxicosis
Thyrotoxicosis - complications
Thyrotoxicosis - genetics
Thyrotoxicosis - therapy
title A Mutation in the KCNE3 Potassium Channel Gene Is Associated with Susceptibility to Thyrotoxic Hypokalemic Periodic Paralysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A48%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Mutation%20in%20the%20KCNE3%20Potassium%20Channel%20Gene%20Is%20Associated%20with%20Susceptibility%20to%20Thyrotoxic%20Hypokalemic%20Periodic%20Paralysis&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Dias%20Da%20Silva,%20Magnus%20R.&rft.date=2002-11&rft.volume=87&rft.issue=11&rft.spage=4881&rft.epage=4884&rft.pages=4881-4884&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/jc.2002-020698&rft_dat=%3Cproquest_cross%3E72649064%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3163643760&rft_id=info:pmid/12414843&rft_oup_id=10.1210/jc.2002-020698&rfr_iscdi=true